AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03638713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: colonoscopy first
Description: Received water exchange colonoscopy followed by EGD
Study NCT03638713 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EGD first
Description: Received EGD followed by water exchange colonoscopy
Study NCT03322085 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation or cryoballoon
Description: Patients in radiofrequency ablation group receive circumferential pulmonary vein isolation,and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation. And Cryoablation is performed using a single cryoballoon. The diameter of the cryoballoon is determined as 28 mm or 23 mm according to pulmonary venography results.
Study NCT01399255 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Insulin lispro
Description: Dosage form- Subcutaneous Injection
Study NCT01399255 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Description: Dosage form- Subcutaneous Injection
Study NCT01055457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vistakon Investigational Multi-Purpose Solution II
Description: contact lens care solution
Study NCT01055457 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReNu MultiPlus Multi-Purpose Solution
Description: contact lens care solution
Study NCT02542670 — intervention group
Intervention type: GENETIC
Intervention: Whole genome sequencing
Description: At least 50 ng of tumor DNA will be extracted from FFPE samples and/or fresh tissue and used for hybridization capture and NGS using the IlluminaMiSeqDx platform.
Study NCT00866060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: 20mg memantine
Study NCT00866060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Memantine
Description: 20mg memantine
Study NCT00866060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: 10mg donepezil
Study NCT00866060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil
Description: 10mg donepezil
Study NCT00866060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo donepezil
Description: Placebo donepezil
Study NCT00866060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo memantine
Description: Placebo memantine
Study NCT02927184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VK2809
Study NCT02927184 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03825107 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patching
Description: covering the fellow eye with an eyepatch to force use of the amblyopic eye
Study NCT03825107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dichoptic videos
Description: watching contrast-rebalanced dichoptic videos to allow the two eyes to work together
Study NCT03735121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the schedule specified in arm or cohort.
Study NCT03735121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: rHuPH20 will be administered as per the scheduled specified in the cohort for Part 1.
Study NCT06090929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STN-DBS
Description: STN-DBS was implanted according normal process
Study NCT00148525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognitive Theory
Description: 6 mo dietary intervention. This arm received an diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on social cognitive theory.
Study NCT00148525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: goal system theory
Description: This arm received a 6 mo diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on goal systems theory and delivered by an automated telephone system.
Study NCT01948349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tongue scraping
Description: Two of four groups will use tongue scraping in conjunction with a normal oral hygiene protocol.
Study NCT01948349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bracket design
Description: Two groups will be allocated to have self-ligating (Carriere) brackets. The other two groups will receive standard twin brackets.
Study NCT00899600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Peripheral provision of 0.5mg/kg of ketamine on induction followed by a 10mcg/kg/min infusion until surgical wound closure
Study NCT00899600 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline at same rate as the previously described ketamine infusion (10mcg/kg/min), same amount of ketamine/placebo syringe on induction (0.5mg/kg).
Study NCT00784706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EP
Description: Participants were asked to wear glasses with a patch on the right lens to block the visual stimuli from the right side and force them to receive the stimuli from the left-side visual field.
Study NCT00784706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIT
Description: The CIT addressed forced use of the affected UE and restricted the unaffected UE during training. Shaping skills were delivered while participants were forced to use their affected UE in the mass practice of functional tasks, such as drinking water and opening a jar. Participants wore a mitt on their unaffected hand and wrist for 6 hours/day during the 3-week training and reported their compliance in a daily log.
Study NCT00784706 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: Traditional occupational therapy matched in intensity and duration with the other groups. The training program included stretching and weight bearing of the affected UE, improving the range of motion of the affected UE, muscle strengthening, and the practice of tasks used for functional training might involve the unaffected UE to assist in the affected UE; for example, stabilizing a bottle while opening its lid or moving pegs into holes on a board.
Study NCT01231828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-carnitine
Description: L-carnitine 4g per day (4 bottles of 10ml).
Study NCT01231828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: Lactulose (30-60 ml per day)
Study NCT01010061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorambucil
Description: Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
Study NCT03860662 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nociceptor flexor reflex
Description: The nociceptive flexion reflex (NFR) is a physiological, polysynaptic reflex allowing for painful stimuli to activate an appropriate withdrawal response
Study NCT03243955 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Verum TEAS
Description: TENS unit with electrodes applied to acupuncture point locations
Study NCT03243955 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TEAS
Description: TENS unit with electrodes applied to non-acupuncture point locations
Study NCT02224274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Study NCT02224274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Study NCT00367341 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: escitalopram
Description: Participants will receive treatment with escitalopram for 12 weeks.
Study NCT00367341 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy (CBT)
Description: CBT will include 16 1 hour sessions provided over 12 weeks.
Study NCT05874336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: Aramchol free acid (3β-arachidylamido-7α,12α-dihydroxy-5β-cholan-24-oic acid) is a synthetic small molecule, produced by conjugation of cholic acid (bile acid) and arachidic acid (saturated fatty acid) linked by a stable amide bond.
Study NCT00774969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole 10% ointment three times a day 7 days
Study NCT00322387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF and plerixafor
Description: G-CSF and plerixafor were administered as described in the treatment arms.
Study NCT03860662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Description: botox
Study NCT01010061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorambucil
Description: Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
Study NCT03860662 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Baclofen
Description: baclofen
Study NCT00929890 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General lifestyle, diet and physical activity counselling
Description: Low-calorie, balanced diet and a general advice on the importance of regular physical activity
Study NCT00929890 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Subject will receive dietary counselling (low-calorie, balanced diet) and will be enrolled in a supervised, 3 times a week, exercise training program
Study NCT03627520 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: [14C]Sulfatinib
Description: 300 mg Sulfatinib with 100 µCi \[14C\]
Study NCT01461564 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: Screening colonoscopy
Study NCT01461564 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Screening colonoscopy
Study NCT03937336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bike Intervention Group
Description: A 1-month biking-based program. The biking program consists of 4 sessions/month of 120 min at physical education lessons in school, and will focus on promote biking through theory and practice lessons about cycle training skills including on-road training
Study NCT02861742 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Delivery of questionnaires
Description: After patient and partner information, clinical research associate or clinical research nurse will give to the couple 2 booklets containing 5 questionnaires, respectively T1, T2, T3, T4 and T5.
Study NCT03699904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valaciclovir
Description: Participants will self-administer Valaciclovir 1 gram three times daily for 8 weeks.
Study NCT02861742 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaire T1 to fill
Description: T1 is to fill before chemotherapy.
Study NCT02861742 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaire T2 to fill
Description: T2 is to fill after the 6th cycle of chemotherapy.
Study NCT02861742 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaire T3 to fill
Description: T3 is to fill at the end of radiotherapy.
Study NCT02861742 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaire T4 to fill
Description: T4 is to fill 4 month after beginning of hormonotherapy or surveillance if no hormonotherapy.
Study NCT02861742 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaire T5 to fill
Description: T5 is to fill 1 year after the beginning of hormonotherapy or surveillance if no hormonotherapy.
Study NCT01375153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BNP
Description: 3.0 pmol/kg/min human active BNP administered as a continuous intravenous infusion during four hours
Study NCT01375153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Description: 0.9% NaCl administered as a continuous intravenous infusion during four hours
Study NCT05944380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% Injectable Solution
Description: 20 mL 0.5% ropivacaine will be injected for the PENG block
Study NCT05944380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0,9% normal saline
Description: 20 mL 0.9% normal saline will be injected for the PENG block
Study NCT00563576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femring®
Description: Estrogen vaginal ring (100 mcg) placed for the first 90 days of Depo-Provera use.~Femring® (estradiol acetate vaginal ring) is a flexible off-white ring designed for vaginal insertion with measurements that include an outer diameter of 56 mm, cross-sectional diameter of 7.6 mm, and core diameter of 2 mm. Femring® 0.1 mg/day has a central core containing 24.8 mg of estradiol acetate which releases at a rate equivalent to 0.1 mg of estradiol per day for 3 months.
Study NCT00563576 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DepoProvera ®
Description: Medroxyprogesterone intramuscular injection comes as a suspension (liquid) to be injected into the buttocks or upper arm. It is usually given once every 3 months (13 weeks), and the recommended dose is 150 mg.
Study NCT00563576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DepoProvera ®
Description: Medroxyprogesterone intramuscular injection comes as a suspension (liquid) to be injected into the buttocks or upper arm. It is usually given once every 3 months (13 weeks), and the recommended dose is 150 mg.
Study NCT03651258 — intervention group
Intervention type: BEHAVIORAL
Intervention: Implementation of ALIJEU
Description: The intervention concerns the passage from the passive feed (gastric tube) to the active feed (breast, feeding bottle).~We propose to set up a pleasant moment just before his meal. This is a practical exercise of a few minutes.~The aim of this special moment is to facilitate child-adult exchanges, improve active food intake and reduce the length of hospital stay.
Study NCT00399880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health literacy intervention
Description: Illustrated medication schedules, pill boxes, pharmacist counseling
Study NCT02040779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate breath-actuated inhaler
Description: Beclomethasone dipropionate (BDP) breath-actuated inhaler (BAI) given in dosages of either 40 mcg/inhalation or 80 mcg/inhalation. Study drug was administered twice each day, in the morning and in the evening, after the completion of the asthma symptom score and the PEF measurements, in that order.
Study NCT02491203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation system
Description: Usual care plus home-based virtual reality telerehabilitation system.
Study NCT03699904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules (containing Avicel blend)
Description: Participants will self-administer two matching placebo capsules (containing Avicel blend) three times daily for 8 weeks.
Study NCT01978392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management group workshops
Description: This intervention consists of multiple group workshop sessions (10 hours total) led by a specially trained facilitator and provided over a span of approximately 2-3 months. The intervention incorporates standard elements of existing evidence-based pain and illness self-management efforts, but tailoring key messages and discussion elements to apply to workplace problems most relevant to workers with chronic medical conditions. Each session is focused on different self-management strategies, with each session containing a mix of facilitator presentation, group discussion, case illustrations, role-play, completion of in-session self-assessments and activities, and brief homework assignments. Approximately equal time is allocated to the topics of improving comfort, modifying work, communicating effectively, applying systematic problem-solving strategies, and dealing with negative thoughts and emotions.
Study NCT01855841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hemin
Description: A single perfusion of 4mg/kg hemin diluted in 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein
Study NCT01855841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A single perfusion of 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein
Study NCT01665976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: film coated tablet, single dose
Study NCT02040779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo breath-actuated inhaler
Description: Placebo was provided in matching breath-actuated inhaler (BAI) devices. The placebo devices were identical to the devices used to deliver active drug. Placebo was administered twice each day, in the morning and in the evening, after the completion of the asthma symptom score and the PEF measurements, in that order.
Study NCT02040779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol/salbutamol
Description: Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period
Study NCT02040779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: albuterol/salbutamol
Description: Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period
Study NCT00315731 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Follicular Lymphoma
Description: For subjects with previously untreated or relapsed follicular or transformed follicular non-Hodgkin's
Study NCT03609723 — intervention group
Intervention type: PROCEDURE
Intervention: CABG
Description: CABG with application of a myocardial protection system (MPS ®) and using a minimal extracorporeal circulation system (MiECC) or CABG without use of a minimal extracorporeal circulation system (Off-pump coronary artery bypass grafting = OPCABG)
Study NCT01451086 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccine made by Beijing Minhai Biotechnology Co., Ltd
Description: Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
Study NCT01451086 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: vaccine made by Chengdu Institute of Biological Products
Description: Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
Study NCT04131777 — intervention group
Intervention type: DEVICE
Intervention: Radiofrequency (RF) catheter
Description: A catheter introduced into the lung lesion via a bronchoscope, used to deliver radiofrequency (RF) energy for the purpose of ablation
Study NCT01665976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: oral suspension, single dose
Study NCT01665976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4927838
Description: hard gelatin capsule, single dose
Study NCT01545414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICBT
Description: 12 weeks of Internet-based Cognitive Behavioral Therapy with a focus on behavioral activation
Study NCT02641028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CERC-501
Description: CERC-501
Study NCT02641028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04130997 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Ublituximab (TG-1101) is a recombinant chimeric monoclonal antibody targeting CD20, available as a 25 mg/mL concentrate for intravenous use, supplied by TG Therapeutics, Inc.
Study NCT01247909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone v penicillin and gentamicin
Description: Ceftriaxone v the standard treatment of infant meningitis (penicillin and gentamicin). Ceftriaxone will be given at a dose of 80mg/kg once a day for at least 14 days.
Study NCT01247909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone v penicillin and gentamicin
Description: Ceftriaxone v the standard treatment of infant meningitis (penicillin and gentamicin). Ceftriaxone will be given at a dose of 80mg/kg once a day for at least 14 days.
Study NCT00790985 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flavocoxid
Description: medical food
Study NCT00790985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: antiinflammatory drug
Study NCT00756509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: 800 mg/d orally
Study NCT03987022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Use of non-steroidal anti-inflammatory drug for pain control postoperatively
Study NCT03987022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioids
Description: Use of narcotic for pain control postoperatively
Study NCT03987022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioids
Description: Use of narcotic for pain control postoperatively
Study NCT03987022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice Packs
Description: Placement of Ice packs on surgical sites postoperatively